Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial

Journal:
The Lancet
Published:
Affiliations:
45
Authors:
47
Institutions Authors Share
Bristol-Myers Squibb, United States of America (USA)
6.000000
0.13
Dana-Farber Cancer Institute (DFCI), United States of America (USA)
2.000000
0.04
Semmelweis University (SE), Hungary
2.000000
0.04
Oslo University Hospital (OUS), Norway
1.000000
0.02
The First Affiliated Hospital of Soochow University, China
1.000000
0.02
Norfolk and Norwich University Hospitals NHS Foundation Trust, United Kingdom (UK)
1.000000
0.02
Princess Margaret Cancer Centre, U of T, Canada
1.000000
0.02
University of South Alabama Mitchell Cancer Institute (USA MCI), United States of America (USA)
1.000000
0.02
Leeds Teaching Hospitals NHS Trust (LTHT), United Kingdom (UK)
1.000000
0.02
Hospital Pablo Tobón Uribe, Colombia
1.000000
0.02
Julián Coronel Medical Center, Colombia
1.000000
0.02
Montefiore Medical Center, Einstein, United States of America (USA)
1.000000
0.02
Royal Adelaide Hospital (RAH), Australia
1.000000
0.02
Taipei Veterans General Hospital (TPEVGH), Taiwan
1.000000
0.02
Tianjin Medical University Cancer Institute and Hospital, TMU, China
1.000000
0.02
IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Italy
1.000000
0.02
Gosford Hospital, Australia
1.000000
0.02
Clínica São Germano, Brazil
1.000000
0.02
Mumbai Oncocare Center, India
1.000000
0.02
University Multidisciplinary Hospital for Active Treatment "St. George" EAD, Bulgaria
1.000000
0.02
Royal Prince Alfred Hospital (RPAH), USYD, Australia
1.000000
0.02
Marien Hospital Düsseldorf, Germany
1.000000
0.02
The University of Hong Kong (HKU), China
1.000000
0.02
London Health Sciences Centre (LHSC), Canada
1.000000
0.02
The Oncology Institute of Hope and Innovation, United States of America (USA)
1.000000
0.02
Musgrove Park Hospital, United Kingdom (UK)
1.000000
0.02
Apollo Hospital - Hyderabad, India
1.000000
0.02
Heidelberg University Hospital at Medical Faculty Heidelberg, Uni Heidelberg, Germany
1.000000
0.02
Gemeinschaftspraxis Dres. Ingo Zander und Eyck von der Heyde Fachärzte für Innere Medizin-Hämatologie und Onkologie, Germany
1.000000
0.02
Sun Yat-sen University Cancer Center (SYSUCC), SYSU, China
1.000000
0.02
Instituto Alexander Fleming, Argentina
1.000000
0.02
IJC-IGTP-ICO, Spain
1.000000
0.02
National Cancer Center Hospital East, Japan
1.000000
0.02
Kyoto Prefectural University of Medicine (KPUM), Japan
1.000000
0.02
Celgene International Sàrl, Switzerland
1.000000
0.02
National and Kapodistrian University of Athens (UOA), Greece
0.500000
0.01
Korea University, South Korea
0.500000
0.01
D'Or Institute for Research and Education (IDOR), Brazil
0.500000
0.01
Federal University of Bahia (UFBA), Brazil
0.500000
0.01
Dalhousie University, Canada
0.500000
0.01
Queen Elizabeth II Health Sciences Centre, Canada
0.500000
0.01
St Vincent's Hospital Melbourne, Australia
0.500000
0.01
The University of Melbourne (UniMelb), Australia
0.500000
0.01
Singapore General Hospital (SGH), Singapore
0.500000
0.01
National Cancer Centre Singapore (NCCS), Singapore
0.500000
0.01